What is an Electronic Clinical Outcome Assessment (eCOA) and why should you consider switching to it from traditional paper-based data collection in your clinical trial? This comprehensive guide details the benefits of eCOA and important considerations for sponsors looking to adopt it.
The drug design process is a challenge in healthcare that calls for the better use of data at every turn. Download this article to uncover four ways pharmaceutical organizations and CROs can leverage patient-generated data from mobile health devices during the drug design process.
Download this case study to learn how Santen Pharmaceutical Co., Ltd, a Japan-based pharmaceutical company specializing in the ophthalmic field, centralized its pharmacovigilance and medical device safety processes with Oracle Argus Cloud, increasing visibility into drug safety data and global regulatory compliance.
With unprecedented levels of information-sharing, life sciences companies need an enterprise content management (ECM) system that will facilitate sharing and yet keep content secure. Doculabs, a consulting firm that specializes in content management, offers an in-depth analysis on how cloud-based ECM provides strategic advantages like easier collaboration. They also share their recommended approach to evaluating cloud ECM platforms, and how to map a transition.
Clinical Ink surveyed 500+ research coordinators and investigators to discover that sites prefer eSource over paper source for clinical trial data capture. Learn how eSource helps sites cut workload in half to improve efficiency, data quality, study timelines and costs.
OmniComm Systems enlisted Applied Clinical Trials to conduct a survey on eSource and discovered our audience needed more tools to understand this growing technology area. Based on the results, they crafted a targeted webinar, a successful white paper and sponsored this eBook that features educational articles around eSource and links to OmniComm resources.
This white paper explores the current landscape of planning trends and challenges in clinical development, and presents solutions and best practices that biopharmaceutical and medical device companies are utilizing to increase planning efficiency.
The new whitepaper, “Digital Capabilities for Clinical Trials in Africa,” discusses how the lack of traditional technology infrastructure in underserved populations offers a “blank slate” environment in which to build new digital models that can be designed to advance research processes worldwide.